Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVRNA012 Omicron BA.5 Booster in Inactivated Vaccine Recipients
NCT05745545Phase 3Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 3 trial of LVRNA012 in coronavirus disease 2019 (COVID-19), sponsored by AIM Vaccine Co., Ltd.. Status: unknown.
02
Drugs
LVRNA012
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05745545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745545.